Respiratory syncytial virus sequencing considerations for an expanded Global Influenza Surveillance and Response System
World Health Organization
jún. 2025 · World Health Organization
Rafbók
35
Síður
family_home
Gjaldgeng
info
reportEinkunnir og umsagnir eru ekki staðfestar Nánar
Um þessa rafbók
In recent years, rapid progress has been made in the development of new pharmaceutical interventions against respiratory syncytial virus (RSV), including monoclonal antibodies (mAbs), vaccines and antivirals. Both passive immunization and active immunization against RSV have now been recommended for infants and older adults in several countries. The ongoing surveillance of RSV viruses is thus vital for identifying the appropriateness of diagnostics and interventions. Establishing a baseline understanding of RSV sequence diversity prior to the widespread rollout of immunization will help to inform the development of new diagnostic and therapeutic products, facilitate assessment of the effectiveness of immunization programmes, better understand viral diversity and evolution, and assess the potential impact of RSV variants on the effectiveness of interventions. This document outlines a number of practical considerations regarding the scale and quality of sequencing. It also outlines the range of next generation sequencing (NGS) technologies suitable for RSV whole genome sequencing (WGS).
Gefa þessari rafbók einkunn.
Segðu okkur hvað þér finnst.
Upplýsingar um lestur
Snjallsímar og spjaldtölvur
Settu upp forritið Google Play Books fyrir Android og iPad/iPhone. Það samstillist sjálfkrafa við reikninginn þinn og gerir þér kleift að lesa með eða án nettengingar hvar sem þú ert.
Fartölvur og tölvur
Hægt er að hlusta á hljóðbækur sem keyptar eru í Google Play í vafranum í tölvunni.
Lesbretti og önnur tæki
Til að lesa af lesbrettum eins og Kobo-lesbrettum þarftu að hlaða niður skrá og flytja hana yfir í tækið þitt. Fylgdu nákvæmum leiðbeiningum hjálparmiðstöðvar til að flytja skrár yfir í studd lesbretti.
